In vivo Reprogramming of Cancer Metabolism by MYC.
In vivo Reprogramming of Cancer Metabolism by MYC.
复制标题
DOI：
10.3389/fcell.2017.00035
复制
发表时间：
2017
影响因子：
5.5
通讯作者：
Goga A
中科院分区：
文献类型：
--
作者：
Camarda R;Williams J;Goga A
在过去的几十年里，我们在理解肿瘤发生过程中代谢改变的功能意义方面取得了巨大的进展。然而，从培养皿中的癌细胞研究得出的许多结论（即，体外）已经受到质疑，因为多条证据已经证明细胞的代谢可以与原发性肿瘤（体内）的代谢显著不同。这一认识，沿着需要识别组织特异性的弱点的驱动致癌基因，导致了越来越多的关注致癌基因依赖的体内代谢编程。癌基因c-MYC（MYC）在多种人类癌症中过表达，虽然其改变细胞代谢的能力已得到充分证实，但将代谢要求和MYC驱动的癌症的脆弱性转化为临床一直受到体外和体内模型不同发现的阻碍。本文综述了MYC在各种癌症模型中对代谢的调节作用，并对MYC的体内调控策略、机制和结论进行了综述。
The past few decades have welcomed tremendous advancements toward understanding the functional significance of altered metabolism during tumorigenesis. However, many conclusions drawn from studies of cancer cells in a dish (i.e., in vitro) have been put into question as multiple lines of evidence have demonstrated that the metabolism of cells can differ significantly from that of primary tumors (in vivo). This realization, along with the need to identify tissue-specific vulnerabilities of driver oncogenes, has led to an increased focus on oncogene-dependent metabolic programming in vivo. The oncogene c-MYC (MYC) is overexpressed in a wide variety of human cancers, and while its ability to alter cellular metabolism is well-established, translating the metabolic requirements, and vulnerabilities of MYC-driven cancers to the clinic has been hindered by disparate findings from in vitro and in vivo models. This review will provide an overview of the in vivo strategies, mechanisms, and conclusions generated thus far by studying MYC's regulation of metabolism in various cancer models.